Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Cobblestone Capital Advisors LLC NY

Cobblestone Capital Advisors LLC NY increased its stake in Merck & Co., Inc. (NYSE:MRK) by 3.6% during the 4th quarter, Holdings Channel reports. The fund owned 44,887 shares of the company’s stock after purchasing an additional 1,549 shares during the quarter. Cobblestone Capital Advisors LLC NY’s holdings in Merck & Co., Inc. were worth $3,672,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in MRK. Spectrum Wealth Advisory Group LLC acquired a new stake in Merck & Co., Inc. in the third quarter valued at $464,000. Perennial Investment Advisors LLC raised its stake in Merck & Co., Inc. by 246.8% in the third quarter. Perennial Investment Advisors LLC now owns 15,518 shares of the company’s stock valued at $1,286,000 after buying an additional 11,043 shares in the last quarter. Cypress Asset Management Inc. TX raised its stake in Merck & Co., Inc. by 0.6% in the third quarter. Cypress Asset Management Inc. TX now owns 59,274 shares of the company’s stock valued at $4,917,000 after buying an additional 377 shares in the last quarter. Clear Harbor Asset Management LLC raised its stake in Merck & Co., Inc. by 1.5% in the third quarter. Clear Harbor Asset Management LLC now owns 37,965 shares of the company’s stock valued at $3,149,000 after buying an additional 570 shares in the last quarter. Finally, Steel Peak Wealth Management LLC raised its stake in Merck & Co., Inc. by 17.6% in the third quarter. Steel Peak Wealth Management LLC now owns 5,822 shares of the company’s stock valued at $483,000 after buying an additional 872 shares in the last quarter. Institutional investors and hedge funds own 72.86% of the company’s stock.

MRK has been the topic of a number of analyst reports. Mizuho restated a “buy” rating and issued a $100.00 price target on shares of Merck & Co., Inc. in a research note on Sunday, December 6th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $95.00 price objective on shares of Merck & Co., Inc. in a report on Tuesday, November 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Merck & Co., Inc. in a report on Friday, February 5th. Finally, SVB Leerink raised their price objective on Merck & Co., Inc. from $100.00 to $103.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Merck & Co., Inc. presently has an average rating of “Buy” and an average target price of $95.36.

Shares of NYSE MRK traded down $0.24 during midday trading on Tuesday, reaching $74.69. 392,683 shares of the company were exchanged, compared to its average volume of 10,548,566. The company has a current ratio of 1.30, a quick ratio of 1.00 and a debt-to-equity ratio of 0.90. Merck & Co., Inc. has a 1 year low of $65.25 and a 1 year high of $87.80. The stock has a fifty day simple moving average of $79.00 and a 200 day simple moving average of $80.98. The stock has a market cap of $188.97 billion, a P/E ratio of 16.58, a PEG ratio of 1.89 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Wednesday, February 3rd. The company reported $1.32 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.38 by ($0.06). Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The company had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.65 billion. During the same period in the prior year, the business earned $1.16 EPS. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. As a group, analysts forecast that Merck & Co., Inc. will post 5.9 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 7th. Shareholders of record on Monday, March 15th will be issued a $0.65 dividend. This represents a $2.60 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date is Friday, March 12th. Merck & Co., Inc.’s dividend payout ratio is presently 50.10%.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products.

Recommended Story: How does new data get added to a blockchain?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.